|
68 Companies |
|
87 Products |
|
87 Products |
|
71 Mechanisms of Action |
|
3 Trials |
|
597 News |
|
| «12345678910111213» |
- Enrollment change, Trial withdrawal, Trial primary completion date: INHEPP;UTINH: Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=0, Withdrawn, Sponsor: University of Utah
N=24 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Feb 2014 --> Dec 2015
- |||| rosiptor (AQX-1125) / Neoleukin Therap
Trial completion: KINSHIP: Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis (clinicaltrials.gov) - Dec 4, 2015
P2, N=54, Completed, Sponsor: Aquinox Pharmaceuticals, Inc.
N=24 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Feb 2014 --> Dec 2015 Active, not recruiting --> Completed
- |||| pegcantratinib (SNA-120) / Sienna
Trial completion: A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis (clinicaltrials.gov) - Nov 26, 2015
P2, N=188, Completed, Sponsor: Creabilis SA
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion, Trial primary completion date: The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis (clinicaltrials.gov) - Nov 19, 2015
P=N/A, N=24, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Aug 2015 --> May 2015
- Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Nov 16, 2015
P2, N=23, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed | Trial primary completion date: Aug 2015 --> May 2015 Trial primary completion date: Jun 2016 --> Dec 2016
- Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Nov 16, 2015
P=N/A, N=2600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Mar 2016
- Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Dec 2015 --> Mar 2016
- Enrollment closed, Trial primary completion date: Cognitive Behavior Therapy for Atopic Dermatitis (clinicaltrials.gov) - Nov 6, 2015
P=N/A, N=25, Active, not recruiting, Sponsor: Karolinska Institutet
Trial primary completion date: Dec 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Dec 2015
- ||| Trial completion: COPES: Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® Regimen (clinicaltrials.gov) - Nov 6, 2015
P=N/A, N=58, Completed, Sponsor: Hyphens Pharma Pte Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Dec 2015 Active, not recruiting --> Completed
- || lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Trial primary completion date: TREBLE: A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 3, 2015
P2, N=200, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Apr 2016
- Furestem-AD (hUCB-MSCs) / Kangstem Biotech
Trial primary completion date: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) (clinicaltrials.gov) - Oct 29, 2015
P1/2, N=34, Completed, Sponsor: Kang Stem Biotech Co., Ltd.
Trial primary completion date: Dec 2016 --> Apr 2016 Trial primary completion date: Aug 2015 --> May 2015
- Enrollment change, Trial withdrawal: 0.005% Sodium Hypochlorite Final Rinse Solution in Atopic Dermatitis (clinicaltrials.gov) - Oct 22, 2015
P1, N=0, Withdrawn, Sponsor: Makati Medical Center
Trial primary completion date: Aug 2015 --> May 2015 N=60 --> 0 | Recruiting --> Withdrawn
- Trial completion, Trial primary completion date: The Effect of Medical Clowns and Topical Anesthetic Cream on Pain and Anxiety in Children Undergoing Allergy Skin Tests (clinicaltrials.gov) - Oct 9, 2015
P=N/A, N=160, Completed, Sponsor: Meir Medical Center
N=60 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | Trial primary completion date: Oct 2012 --> Apr 2014
- Orfadin (nitisinone) / Astellas, SOBI
Trial primary completion date: Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) - Oct 8, 2015
P1/2, N=50, Recruiting, Sponsor: National Eye Institute (NEI)
Recruiting --> Completed | Trial primary completion date: Oct 2012 --> Apr 2014 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial completion, Trial initiation date: The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel (clinicaltrials.gov) - Oct 8, 2015
P=N/A, N=120, Completed, Sponsor: Meir Medical Center
Trial primary completion date: Dec 2015 --> Dec 2016 Not yet recruiting --> Completed | Initiation date: Nov 2012 --> Apr 2015
- | Trial completion: A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants (clinicaltrials.gov) - Oct 6, 2015
P0, N=46, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Completed | Initiation date: Nov 2012 --> Apr 2015 Recruiting --> Completed
- Trial withdrawal: Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB (clinicaltrials.gov) - Oct 1, 2015
P=N/A, N=0, Withdrawn, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Completed Not yet recruiting --> Withdrawn
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed, Trial primary completion date: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Sep 30, 2015
P2, N=184, Active, not recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Nov 2015
- || Dupixent (dupilumab) / Sanofi, Regeneron
Trial primary completion date: Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Sep 25, 2015
P2, N=109, Completed, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Nov 2015 Trial primary completion date: Jul 2013 --> Mar 2013
- Trial completion, Trial primary completion date: Placebo Effect in the Treatment of Atopic Dermatitis (clinicaltrials.gov) - Sep 18, 2015
P=N/A, N=166, Completed, Sponsor: Margitta Worm
Trial primary completion date: Jul 2013 --> Mar 2013 Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Nov 2013
- Biomarker, Enrollment change, Trial primary completion date: Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias (clinicaltrials.gov) - Sep 9, 2015
P=N/A, N=269, Terminated, Sponsor: Duke University
Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Nov 2013 N=28 --> 269 | Trial primary completion date: Dec 2013 --> Feb 2013
- recombinant ectodysplasin A1 (APO200) / Valerio Therap, Pierre Fabre
Enrollment closed, IO biomarker: Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (clinicaltrials.gov) - Sep 8, 2015
P2, N=6, Active, not recruiting, Sponsor: Edimer Pharmaceuticals
N=28 --> 269 | Trial primary completion date: Dec 2013 --> Feb 2013 Recruiting --> Active, not recruiting
- || Enrollment closed: ECP-015: Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia (clinicaltrials.gov) - Sep 8, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: Edimer Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Trial completion, Enrollment change, Trial primary completion date: Probiotics and Allergic Diseases (clinicaltrials.gov) - Sep 3, 2015
P=N/A, N=240, Completed, Sponsor: GenMont Biotech Incorporation
Recruiting --> Active, not recruiting Recruiting --> Completed | N=360 --> 240 | Trial primary completion date: Jun 2013 --> Jun 2014
- | Furestem-AD (hUCB-MSCs) / Kangstem Biotech
Trial completion, Trial primary completion date: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) (clinicaltrials.gov) - Sep 2, 2015
P1/2, N=30, Completed, Sponsor: Kang Stem Biotech Co., Ltd.
Recruiting --> Completed | N=360 --> 240 | Trial primary completion date: Jun 2013 --> Jun 2014 Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Aug 2015
- Enrollment closed: Effect of Holly Mangrove Shower Gel in Atopic Dermatitis Patients (clinicaltrials.gov) - Sep 1, 2015
P3, N=30, Active, not recruiting, Sponsor: Mahidol University
Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Aug 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: Placebo Effect in the Treatment of Atopic Dermatitis (clinicaltrials.gov) - Aug 22, 2015
P=N/A, N=140, Recruiting, Sponsor: Margitta Worm
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2014 --> Oct 2016
- ||| BMS-981164 / BMS
Trial completion: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (clinicaltrials.gov) - Aug 19, 2015
P1, N=93, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2014 --> Oct 2016 Recruiting --> Completed
- Reimbursement, Trial primary completion date: Evaluation of an Integrated Care Project (clinicaltrials.gov) - Aug 15, 2015
P=N/A, N=3960, Enrolling by invitation, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed Trial primary completion date: Mar 2015 --> Nov 2015
- Chanllergen (dermatophagoides farinae sublingual drops) - Zhejiang Wolwo Bio / Pharma
Trial completion, Trial primary completion date: Sublingual Immunotherapy in Patients With Atopic Dermatitis (clinicaltrials.gov) - Aug 14, 2015
P2, N=240, Completed, Sponsor: Zhejiang University
Trial primary completion date: Mar 2015 --> Nov 2015 Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jun 2015
- Trial primary completion date: Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=2, Terminated, Sponsor: Cosmetique Active International
Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jun 2015 Trial primary completion date: Mar 2015 --> Feb 2013
- Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=2600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2015 --> Feb 2013 Trial primary completion date: Apr 2015 --> Dec 2015
- Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Apr 2015 --> Dec 2015 Trial primary completion date: Apr 2015 --> Dec 2015
- Stelara (ustekinumab) / J&J
Clinical: Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis (clinicaltrials.gov) - Aug 13, 2015
P2, N=32, Active, not recruiting, Sponsor: Rockefeller University
Trial primary completion date: Apr 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- | difamilast (MM36) / Otsuka, Medimetriks
Trial completion: A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects (clinicaltrials.gov) - Aug 13, 2015
P1, N=32, Completed, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| KHK4577 / Kyowa Kirin
Trial completion, Trial primary completion date: Phase 2 Study of KHK4577 (clinicaltrials.gov) - Aug 11, 2015
P2, N=93, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Dec 2014
- ||||| Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment closed, Monotherapy: SOLO 1: Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Aug 6, 2015
P3, N=600, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Dec 2014 Recruiting --> Active, not recruiting
- ||||| Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment closed: CHRONOS: Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Aug 6, 2015
P3, N=700, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Biomarker, Trial completion: Biomarkers in Vascular Ehlers-Danlos Syndrome (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=211, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting Recruiting --> Completed
- | betamethasone/dexchlorpheniramine maleate / Generic mfg., prednisolone / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment (clinicaltrials.gov) - Jul 14, 2015
P3, N=140, Recruiting, Sponsor: EMS
Recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Oct 2013 --> Feb 2014 | Trial primary completion date: Jun 2014 --> Mar 2016
- | Zoryve (roflumilast cream) / Arcutis
Trial initiation date: Topical Roflumilast in Adults With Atopic Dermatitis (clinicaltrials.gov) - Jul 9, 2015
P2, N=40, Completed, Sponsor: Takeda
Not yet recruiting --> Recruiting | Initiation date: Oct 2013 --> Feb 2014 | Trial primary completion date: Jun 2014 --> Mar 2016 Initiation date: Feb 2013 --> Jun 2013
- Trial completion, IO biomarker: ADRN Barrier/Immunoprofiling Exploratory Pilot Study (clinicaltrials.gov) - Jul 8, 2015
P=N/A, N=150, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Feb 2013 --> Jun 2013 Active, not recruiting --> Completed
- cyclosporin A microemulsion / Generic mfg.
Trial completion: Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis (AD) With Suppression of Immune Activation During Cyclosporine A Therapy (clinicaltrials.gov) - Jun 30, 2015
P=N/A, N=9, Completed, Sponsor: Rockefeller University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || AIMab7195 / Nestle
Enrollment change, Trial primary completion date: Safety and Tolerability of XmAb (clinicaltrials.gov) - Jun 30, 2015
P1, N=88, Recruiting, Sponsor: Xencor, Inc.
Active, not recruiting --> Completed N=64 --> 88 | Trial primary completion date: Mar 2015 --> Mar 2016
- Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Jun 11, 2015
P2, N=23, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=64 --> 88 | Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: Jan 2016 --> Jun 2016
- Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: A Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=0, Withdrawn, Sponsor: Seton Family of Hospitals
Trial primary completion date: Jan 2016 --> Jun 2016 N=50 --> 0 | Initiation date: Mar 2014 --> Jan 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2014 --> Apr 2015
- SB011 / Sterna Biologicals
Trial primary completion date: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema (clinicaltrials.gov) - Jun 11, 2015
P2a, N=26, Recruiting, Sponsor: Sterna Biologicals GmbH & Co. KG
N=50 --> 0 | Initiation date: Mar 2014 --> Jan 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2014 --> Apr 2015 Trial primary completion date: Jul 2014 --> Jul 2015
- | Enrollment closed, Trial primary completion date: Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) (clinicaltrials.gov) - Jun 9, 2015
P1/2, N=15, Active, not recruiting, Sponsor: TransDerm, Inc.
Trial primary completion date: Jul 2014 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Oct 2015
- |||| Trial completion: A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis (clinicaltrials.gov) - Jun 6, 2015
P4, N=107, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Oct 2015 Recruiting --> Completed
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment closed, Enrollment change: Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) (clinicaltrials.gov) - Jun 3, 2015
P2, N=6, Active, not recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting --> Completed Recruiting --> Active, not recruiting | N=15 --> 6